Alosetron and irritable bowel syndrome

Area of Science:

• Gastroenterology
• Pharmacology
• Neuroscience

Background:

• Alosetron is a selective 5-HT(3)-receptor antagonist approved for women with refractory diarrhea-predominant irritable bowel syndrome (IBS).
• Previous studies indicate alosetron improves IBS symptoms, abdominal pain, bowel function, and quality of life (QOL).

Purpose of the Study:

• To review recent preclinical and clinical data on alosetron's effects on gastrointestinal motility, visceral sensitivity, and anxiety.
• To discuss the impact of alosetron on QOL in IBS patients and its safety profile.

Main Methods:

• Review of preclinical animal studies investigating 5-HT(3) receptor involvement in gastrointestinal function.
• Analysis of clinical data from IBS patients treated with alosetron, including QOL assessments.
• Examination of human brain imaging studies and genetic factor investigations related to alosetron response.

Main Results:

• Alosetron demonstrates beneficial effects on global IBS symptoms, abdominal pain, and altered bowel function.
• Evidence suggests both peripheral (gastrointestinal) and potential central mechanisms of action.
• Alosetron shows greater efficacy in women, with ongoing research into genetic influences on response.

Conclusions:

• Alosetron is an effective treatment for specific IBS populations, impacting motility, sensitivity, and potentially anxiety.
• Key considerations include its effectiveness in women and the most frequent adverse event, constipation.
• Further research is investigating genetic factors and central mechanisms to optimize alosetron therapy.